Stock flies high on Clear­side’s PhI­II mac­u­lar ede­ma tri­al re­sults as drug im­proves vi­sion

The stock is soar­ing at Clear­side Bio­med­ical $CLSD, a Geor­gia-based bio­phar­ma de­vel­op­ing eye drugs that tack­le blind­ness, fol­low­ing news that one of its treat­ment im­proved …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.